Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
For knowledge about patent expiration dates and ongoing patent challenges
— Generic pharma, Canada
To know which brands are on and off patent
— Advertising sales pharma companies, USA
To find expiring patents for generic product development
— Product manager, Saudi Arabia
To monitor patent expirations/loss of exclusivity
— Pharmacy director, USA
For patent information on systemic antifungals
— Portfolio specialist, USA
Generated: May 24, 2017
These international patent data are derived from patent families, based on US drug-patent linkages.
Accordingly, they should not be regarded as comprehensive records of ex-US drug-patent associations.
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,062,665 | Feb 1, 2028 | Novartis Pharms Corp | PROMACTA | eltrombopag olamine | |||||||||||||||||||||||||
| 8,828,430 | Feb 1, 2028 | Novartis Pharms Corp | PROMACTA | eltrombopag olamine | |||||||||||||||||||||||||
| 8,052,993 | Feb 1, 2028 | Novartis Pharms Corp | PROMACTA | eltrombopag olamine | |||||||||||||||||||||||||
| 8,052,994 | Feb 1, 2028 | Novartis Pharms Corp | PROMACTA | eltrombopag olamine | |||||||||||||||||||||||||
| 8,071,129 | Feb 1, 2028 | Novartis Pharms Corp | PROMACTA | eltrombopag olamine | |||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
To learn about drugs that will be coming off patent and to offer an ANDA in their master drug file
— Global market development manager, healthcare packaging provider, USA
To get information on drug patent expirations
— Analyst, USA
For patent information on systemic antifungals
— Portfolio specialist, USA
To get information about patented drugs: Expiration of patents, information about new drugs, and potential new drug therapies.
— Director, pharmacy services, USA
To gain information on when to expect generics on the market in order to inform patients of when they can expect more affordable drugs
— Retail pharmacist, USA
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
